BCOR and sarcoma: Overall, the 3 year‐EFS were 44.0% (95% CI 28.7–67.5) and 41.2% (95% CI 25.4–67.0) for “CIC fused sarcoma” and “BCOR rearranged sarcoma” groups, respectively (p = 0.97).